Adrenergic signaling and cancer progression
Adrenergic signaling and cancer progression
Project number : 239661
Created by: Katja Fall, 2017-12-19
Last revised by: Katja Fall, 2019-03-28
Project created in: FoU Region Örebro län

PublishedPublished
2012-01-01
Rekrytering/datainsamling pågår

Titel och sammanfattning

Populärvetenskaplig sammanfattning

There is increasing evidence that neuroendocrine signalling may play a role in cancer progression. We are exploring the role of b-adrenergic signalling in cancer progression using several existing data sources, including nationwide population registers and two well-characterized prostate cancer patient cohorts for which detailed data are available. Including studies of gene expression patterns in individual tumours to population level data analyses on prescribed medication use among cancer patients our data, we hope to advance the understanding of b-adrenergic signalling in cancer pathogenesis and the potential role of b-adrenergic receptors as targets for therapeutic intervention.

Projektspecifik information

Ämnesord

checked Cancer och onkologi
checked Epidemiologi


(Only selected options are displayed. Click here to display all options)

Studietyp

Observationsstudie

Diagnoskod för huvuddiagnos

C60-C63 Maligna tumörer i de manliga könsorganen

Multicenterstudie

Nej

Inklusionsstatus

 Planerat antalAntal tillfrågadeScreen-failureAntal randominserade
n=50000   

Vetenskaplig sammanfattning

We use prospectively collected data available through national Swedish registers to conduct cohort studies on beta-blocker use and cancer survival. From the Swedish Cancer Register we identify patients diagnosed with cancer from January 1, 2006 and onwards, using the International Classification of Diseases (ICD) 7th. Information on tumour stage and histology, year of diagnosis, and age at diagnosis is available through the register.

Prescriptions of β-blockers and other antihypertensive medications around the time of cancer diagnosis are identified from the Prescribed Drug Register using the Anatomic Therapeutic Chemical (ATC) classification system. The number of distinct medication classes (medications with the same initial five characters of ATC classification) are used to derive a medication-basedcomorbidity score to account for overall disease burden.

Linkages to the Patient Register enables access to data on comorbidity, the Total Population Register provides migration data, and LISA (Longitudinal Database of Education, Income and Occupation) information about attained education, marital status and region of residence. The Causes of Death Register provides information on the underlying cause of death.

Involverade parter

Arbetsplats

Added workplaces

Regioner - Region Örebro Län - Hälso- och sjukvård - Övrigt workplace verified by Region Örebro län on 2018-06-14

Sponsor

Added workplaces

Regioner - Region Örebro Län - Hälso- och sjukvård - Övrigt workplace verified by Region Örebro län on 2018-06-14

Slutrapport

Publikationer

  1. Udumyan R, Montgomery S, Fang F, Almroth H, Valdimarsdottir U, Ekbom A, Smedby KE, Fall K.
    Cancer Res. 2017:77(13):3700-3707.

Adrenergic signaling and cancer progression, from FoU Region Örebro län
http://www.researchweb.org/is/en/fourol/project/239661